Eyeing Returns: Aldeyra’s Shift From Lab To Market (NASDAQ:ALDX)

At a Glance

Building on my prior bullish stance, Aldeyra Therapeutics (NASDAQ:ALDX) finds itself at an inflection point. The company’s Q2 2023 earnings report reveals a significant 52% cut in R&D spending, hinting at a shift from drug development

Read the full article here